Ipamorelin is a synthetic pentapeptide that has been studied in laboratory settings as a selective growth-hormone secretagogue (GHS). For researchers asking what is ipamorelin, the short answer is that it is a ghrelin-receptor agonist first characterized in the late 1990s and investigated in preclinical models for its ability to stimulate growth-hormone release. This overview summarizes what peer-reviewed and preclinical research has examined about the compound, framed strictly for scientific and educational understanding.
What Is Ipamorelin at the Molecular Level
Ipamorelin has the amino-acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was identified during a medicinal-chemistry program as a compound derived from the growth hormone-releasing peptide (GHRP)-1 series, notably lacking the central Ala-Trp dipeptide found in earlier GHRPs. In the foundational characterization by Raun and colleagues, ipamorelin was described as a pentapeptide that released growth hormone (GH) from primary rat pituitary cells with potency and efficacy comparable to GHRP-6 in vitro and in vivo. Because it acts at what the original researchers called a “GHRP-like receptor” — later understood as the growth hormone secretagogue receptor (GHSR), the same receptor targeted by the endogenous peptide ghrelin — ipamorelin is often described in the literature as a ghrelin mimetic.
Where It Sits Among Growth-Hormone Secretagogues
Growth-hormone secretagogues are a broad class of peptides and small molecules studied for their capacity to prompt GH release through the ghrelin/GHSR pathway rather than through growth hormone-releasing hormone (GHRH). GHRP-6 and GHRP-2 are earlier members of this class. Investigators have also noted that GHRPs accumulate in the glandular stomach, the site of ghrelin synthesis, and that resection of the gastrointestinal tract attenuated the GH response to GHRP-6 in rats — a line of research that examined whether GHRPs act, in part, by engaging the ghrelin system.
Selectivity: The Feature Most Studied in the Research
The characteristic that distinguished ipamorelin in the early literature was its reported selectivity. In conscious swine, the original investigators reported that ipamorelin did not raise plasma ACTH or cortisol to levels significantly different from those seen after GHRH stimulation, even at doses far above the threshold for GH release. By contrast, GHRP-6 and GHRP-2 in the same study were associated with increased ACTH and cortisol. On this basis the authors described ipamorelin as the first GHS with a selectivity for GH release resembling that of GHRH. None of the secretagogues tested measurably affected FSH, LH, prolactin, or TSH in that work. It is worth emphasizing that these are findings from animal and in vitro models, and selectivity observed preclinically does not automatically translate to any conclusion about human use.
What Preclinical Research Has Investigated
Beyond the initial pharmacology, ipamorelin has appeared in several preclinical studies exploring GH-related physiology in rodents. These investigations were designed to probe mechanism and are limited to animal models:
- Somatotroph biology. A study in young female rats examined how chronic administration influenced the pituitary somatotroph cell population and intracellular GH content, reporting changes in secretory-granule density and dynamic control over GH content.
- Nitrogen and protein metabolism. In a steroid-treated rat model, researchers studied effects on hepatic amino-nitrogen conversion and whole-body nitrogen balance, observing that the secretagogue counteracted some catabolic effects of prednisolone, though less efficiently than GH itself at the doses used.
- Bone and muscle under glucocorticoid stress. In an adult-rat model, investigators reported that co-administration with a glucocorticoid was associated with increased periosteal bone-formation rate and calf-muscle tetanic tension relative to glucocorticoid alone.
- Gastrointestinal motility. In a rodent model of postoperative ileus, a ghrelin-mimetic profile was studied in relation to gastrointestinal transit, reflecting the receptor’s known expression in the gut.
The ghrelin receptor targeted by these compounds has itself been of interest beyond GH biology; medicinal-chemistry work has explored ipamorelin-related peptidomimetics as scaffolds for positron-emission-tomography probes intended to image GHSR expression in disease.
Clinical Trial Record
The publicly registered clinical trial record for ipamorelin is limited. According to ClinicalTrials.gov, the compound was evaluated in two completed Phase II studies sponsored by Helsinn Therapeutics that examined its safety and efficacy for postoperative ileus and for recovery of gastrointestinal function following bowel resection. These registrations reflect an investigational history focused on gastrointestinal motility rather than on any approved therapeutic indication. Ipamorelin is not an approved drug, and the body of human data remains preliminary.
Interpreting the Ipamorelin Research Literature
Reading the primary literature on what is ipamorelin shows a compound defined chiefly by a well-characterized preclinical pharmacology, a distinctive selectivity profile in animal models, and a narrow, unfinished clinical record. Much of what is publicly known rests on rodent and swine studies and early-phase trials. Evidence-literate interpretation means separating the mechanistic findings that these studies actually report from broader claims that the data do not support.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. doi:10.1530/eje.0.1390552
- Ahnfelt-Rønne I, et al. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001. doi:10.1385/ENDO:14:1:133
- Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001. doi:10.1054/ghir.2001.0239
- Jiménez-Reina L, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin in young female rats: somatotroph response in vitro. Histol Histopathol. 2002. doi:10.14670/HH-17.707
- Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009. doi:10.1016/j.ghir.2009.01.001
- Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur J Med Chem. 2018. doi:10.1016/j.ejmech.2018.08.062
- Ipamorelin for the management of post-operative ileus (Phase II). ClinicalTrials.gov. NCT00672074
- Ipamorelin for recovery of gastrointestinal function after bowel resection (Phase II). ClinicalTrials.gov. NCT01280344
Research Use Only. Ipamorelin is a research compound intended solely for laboratory and scientific investigation. It is not a drug, dietary supplement, or approved therapeutic, and it is not intended for human or animal consumption or for the diagnosis, treatment, cure, or prevention of any disease or condition. The information above is educational, summarizes published preclinical and early clinical research, and does not constitute medical advice or any recommendation for use.